Johnson & Johnson Pharmaceuticals Leader Jennifer Taubert to Retire

Dow Jones08-04 23:00

Johnson & Johnson said Jennifer Taubert, the head of its $60 billion pharmaceuticals business, is retiring after more than two decades with the drugmaker.

J&J on Tuesday said Tom Cavanaugh will succeed Taubert as executive vice president and worldwide chairman of innovative medicine on Sept. 1.

J&J's innovative-medicine business, which includes such blockbuster drugs as Darzalex, Tremfya and Stelara, accounted for $31.8 billion of the New Brunswick, N.J., company's first-half sales of $49.4 billion.

Taubert, who joined J&J in 2005, has been in her current post and member of the company's executive committee since 2018.

Cavanaugh, who joined J&J in 2017, currently serves as group chairman, North America, for innovative medicine and will also succeed Taubert on the executive committee, J&J said.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment